Literature DB >> 22578724

Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy.

Dan Leibovici1, Edmond Chiong, Louis L Pisters, Charles C Guo, John F Ward, Lizmarie Andino, Ina N Prokhorova, Patricia Troncoso.   

Abstract

PURPOSE: Focal therapy is currently under investigation as an alternative to salvage radical prostatectomy for locally recurrent prostate cancer after primary radiation therapy. If patients can be selected properly, focal therapy could enable tumor eradication without the morbidity associated with salvage radical prostatectomy. We describe the pathological features of recurrent prostate cancer in salvage radical prostatectomy specimens and the implications of these results for focal therapy.
MATERIALS AND METHODS: We gathered data on 50 consecutive patients who had recurrence after primary radiation therapy and underwent salvage radical prostatectomy between 1993 and 2008. Preoperatively prostate specific antigen was less than 10 ng/ml in 49 patients (98%) and biopsy Gleason score was 7 or less in 18 (36%). Salvage radical prostatectomy specimens were analyzed for tumor zonal origin, site and volume, Gleason score and pathological stage.
RESULTS: Median preoperative prostate specific antigen was 3.4 ng/ml. Pathological stage was T2 in 23 patients (46%). The salvage radical prostatectomy Gleason score was 7 or less in 17 patients (34%) and surgical margins were negative in 43 (86%). A single cancer focus was found in 33 cases (66%) while there was bilateral involvement in 37 (74%). The base and apex were involved in 23 cases (46%) and 37 tumors (74%) were located within 5.0 mm of the urethra. Median tumor volume was 1.27 cm(3) (range 0.05 to 12.96).
CONCLUSIONS: Prostate cancer recurrence after radiation therapy is often bilateral and involves multiple zones. It is often high grade, bulky and close to the urethra. These findings suggest that planning salvage focal therapy after radiation failure will be difficult.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578724     DOI: 10.1016/j.juro.2012.02.2571

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Prostate cancer: Focal cryotherapy freezes recurrent disease in its tracks.

Authors:  Gautum Agarwal; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2013-08-27       Impact factor: 14.432

2.  Prostate cancer: Post-treatment imaging-a desperate need for solid evidence.

Authors:  Olivier Rouvière
Journal:  Nat Rev Urol       Date:  2015-04-28       Impact factor: 14.432

3.  Salvage prostate brachytherapy after definitive external radiation: tried and now tested.

Authors:  Young Kwok; Mannat Narang; Jason K Molitoris
Journal:  Transl Androl Urol       Date:  2019-07

4.  Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.

Authors:  Toshikazu Takeda; Amy L Tin; Renato B Corradi; Maha Mamoor; Nicole E Benfante; Daniel D Sjoberg; Peter T Scardino; James A Eastham; Samson W Fine; Karim A Touijer
Journal:  Eur Urol       Date:  2017-08-26       Impact factor: 20.096

Review 5.  Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer.

Authors:  A Kanthabalan; M Arya; S Punwani; A Freeman; A Haroon; J Bomanji; M Emberton; H U Ahmed
Journal:  World J Urol       Date:  2013-12       Impact factor: 4.226

6.  Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer.

Authors:  Gregory T Chesnut; Amy L Tin; Arjun Sivaraman; Toshikazu Takeda; Taehyoung Lee; Jonathan Fainberg; Nicole Benfante; Daniel D Sjoberg; Hebert Alberto Vargas; Samson W Fine; Peter T Scardino; James A Eastham; Jonathan A Coleman; Karim A Touijer; Michael J Zelefsky; Behfar Ehdaie
Journal:  Urol Oncol       Date:  2021-02-12       Impact factor: 2.954

7.  miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).

Authors:  Xiaoyong Huang; Samira Taeb; Sahar Jahangiri; Elina Korpela; Ivan Cadonic; Nancy Yu; Sergey N Krylov; Emmanouil Fokas; Paul C Boutros; Stanley K Liu
Journal:  Oncotarget       Date:  2015-09-08

Review 8.  Salvage local therapy for radiation-recurrent prostate cancer - where are we?

Authors:  Romuald Zdrojowy; Janusz Dembowski; Bartosz Małkiewicz; Krzysztof Tupikowski; Wojciech Krajewski
Journal:  Cent European J Urol       Date:  2016-07-04

Review 9.  Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review.

Authors:  D A Smit Duijzentkunst; M Peters; J R N van der Voort van Zyp; M A Moerland; M van Vulpen
Journal:  World J Urol       Date:  2016-03-24       Impact factor: 4.226

10.  Prostate Cancer - Local Treatment after Radiorecurrence: Surgery - Back to the future?

Authors:  Leonardo O Reis; Paul L Nguyen
Journal:  Int Braz J Urol       Date:  2018 May-Jun       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.